SCHEMBL6931979

SCHEMBL6931979

O=C(Cc1ccccn1)Nc1cccc2oc(Nc3cccc(Cl)c3)nc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.58
RAB9A P51151 5/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 2/20 0.47
GRM4 Q14833 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
CHUK O15111 1/20 0.42
ICOSLG O75144 1/20 0.42
ICOS Q9Y6W8 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2134679 0.79 RAB9A (0.67) RAB9ANPC1MAPTGRM4HDAC6
SCHEMBL31240480 0.69 GSK3A (0.63) RAB9ANPC1MAPTCHUKICOSLG
SCHEMBL6929774 0.69 F2 (0.51) F2RAB9ANPC1MAPTALDH1A1
SCHEMBL3948210 0.68 KDM4E (0.53) F2RAB9ANPC1MAPTGRM4
SCHEMBL6931474 0.68 F2 (0.86) F2RAB9ANPC1MAPTALDH1A1
SCHEMBL3453018 0.68 CA1 (0.67) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL2028409 0.67 CA1 (0.69) RAB9ANPC1HDAC6MEN1KMT2A
SCHEMBL3949035 0.66 NPC1 (0.71) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL27456492 0.66 MEN1 (0.51) F2RAB9ANPC1MAPTHDAC6
SCHEMBL9718845 0.66 RAB9A (0.60) F2RAB9ANPC1MAPTHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225131-A1 Thrombin inhibitors BURGEY CHRISTOPHER S (US) 2003-12-04 US claimed
US-20030225131-A1 Thrombin inhibitors BURGEY CHRISTOPHER S (US) 2003-12-04 US disclosed
US-20030225131-A1 Thrombin inhibitors BURGEY CHRISTOPHER S (US) 2003-12-04 US disclosed
US-20030225131-A1 Thrombin inhibitors BURGEY CHRISTOPHER S (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225131-A1 Thrombin inhibitors TFPI, SERPINC1, PLAT F2 5/4885RAB9A 1208/4885NPC1 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.